Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2010

View Archived Issues

Several phase II/III trials show safety and efficacy of fingolimod in relapsing-remitting MS

Ganglioside vaccine NeuGcGM3/VSSP shows promise in melanoma

MEDI-8662 and CAIV-T flu vaccines demonstrate comparable safety/immunogenicity in phase III trial

FDA accepts for review GSK's response regarding Horizant in restless legs syndrome

Array Biopharma discloses promising preclinical data on ARRY-575

Pentraxin-3 has therapeutic activity in mice with P. aeruginosa lung infection

PCI-45292 more potent than PCI-32765 in arthritis models

Biocartis and bioMerieux partner to develop molecular diagnostics

Prana Biotechnology plans to conduct phase IIb PBT-2 trial in Alzheimer's disease

EVP-6124 enhances cognition as coagonist with acetylcholine

Boehringer Ingelheim claims new chemokine CCR3 receptor antagonists

FDA supports Pozen's design of phase III PA-32540 trial

Merck Serono discovers new DHOdehase inhibitors

New allosteric modulators of metabotropic glutamate mGlu1 receptor claimed

Ardea Biosciences reports data on RDEA-594 in gout

Pfizer presents novel mineralocorticoid receptor antagonists

Aeterna Zentaris identifies new quinaxoline derivatives for cancer therapy

Lilly to acquire Avid Radiopharmaceuticals

Raptor Pharma begins phase II DR cysteamine trial in Huntington's disease

StemCells to receive U.S. government grants to support stem cell projects

Genta begins phase IIb tesetaxel trial in metastatic breast cancer

Clinuvel receives FDA guidance on Scenesse program in erythropoietic protoporphyria

FDA approves IND for phase I/II development of RetinoStat in wet AMD

Results reported from phase III BLOOM-DM weight loss study in type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...